Based on non-human primate models, it is estimated that protection is definitely accomplished at serum antibody concentrations 50C100-fold higher than the measured IC50 of the challenge (infecting) virus5. Participants were randomly assigned to one of three organizations at a 1:1:1 percentage of VRC01 10 mg/kg, VRC01 30 mg/kg, or placebo (Number 1A). weeks after 1st infusion. Results: The median HVTN 704/HPTN 085 participant age was 28; 99% were assigned male sex; 90% identified as cisgender male, 5% as TG female and the remaining as additional genders. Thirty-two percent were White, 15% Black and 57% Hispanic/Latinx. Twenty-eight percent experienced a sexually transmitted illness at enrollment. Over 23,000 infusions were administered with PU 02 no severe IV administration complications. Overall retention and adherence to the study routine exceeded 90%, and the drop-out rate was below 10% yearly (7.3 per 100-person years) through Week 80, the last visit for the primary endpoint. Conclusions: HVTN 704/HPTN 085 exceeded accrual and retention anticipations. With exceptional security of IV administration and operational feasibility, it paves the way for future large-scale mAb tests for HIV prevention and/or treatment. Keywords: VRC01, bnAb, HIV, passive immunization, AMP studies, HVTN 704/HPTN 085 Intro Approximately 1. 7 million people acquired HIV in 2018 globally, despite the availability of multiple prevention methods1. Attempts to increase the available options have been invigorated by improvements in B-cell immunology and solitary cell antibody cloning techniques over the past decade leading to the finding of broadly neutralizing antibodies (bnAbs) that neutralize multiple HIV-1 variants (breadth) at numerous concentrations (potency) in vitro2. Reduction of simian immunodeficiency computer virus and simian HIV (SHIV) acquisition in nonhuman primate (NHP) models by highly potent broadly neutralizing monoclonal antibodies (mAbs) at serum concentrations attainable by intravenous (IV) or subcutaneous (SC) injection has been demonstrated3C5. The feasibility of administering physiological doses of monoclonal antibodies (mAbs) offers led to advancement in medical tests. A fundamental medical question remains as to whether passive transfer of HIV-1 mAbs is definitely efficacious in avoiding sexual transmission of HIV-1 in revealed individuals. Whereas passive administration of total IgG for pre- or post-exposure prophylaxis of bacterial and viral diseases such as tetanus, hepatitis A/B, and varicella have been routine medical practice for decades6, only palivizumab (a human being mAb) has been licensed for use (prevention of respiratory syncytial computer virus illness)7. For HIV, select mAbs are effective in reducing viremia in analytical treatment interruption studies of people living with HIV8,9. Highly potent CD4 binding site mAbs such as VRC01, VRC07C523 and 3BNC117 clogged HIV transmission in NHP/SHIV models and have shown security and tolerability in phase 1 clinical tests8. Moreover, a strong association is present between serum neutralization PU 02 and ID50 titers required for safety in NHP/SHIV models10. Security and pharmacokinetics of VRC01 given IV or SC have been evaluated in early phase tests. These data supported screening VRC01 in phase 2b efficacy tests to evaluate its effect on reducing HIV-1 acquisition. The HIV Vaccine Tests Network (HVTN) and HIV Prevention Tests Network (HPTN) partnered to conduct the Antibody Mediated Prevention (AMP) tests, HVTN 704/HPTN 085 (#NCT02716675) and HVTN 703/HPTN 081 (#NCT02568215). HVTN PU 02 703/HPTN 081 enrolled cisgender women in sub-Saharan Africa, with feasibility and enrollment results reported inside a parallel manuscript. Here, we statement on the design, enrollment, baseline steps, and retention of HVTN 704/HPTN 085, which was carried out in cisgender males and transgender (TG) populations in Brazil, Peru, Switzerland, and the US. METHODS Protocol development Dose and administration routine were based upon the PK and security profile of two VRC01 phase 1 tests11C13. IV administration was selected to accomplish VRC01 concentration and serum neutralizing antibody titers required to prevent HIV-1 acquisition. PU 02 VRC01 PK studies indicated a plasma half-life of 15 days, with rapid decrease in plasma levels post-infusion and a slower decrease over the following 8 weeks, and an estimated mean trough concentration of 6 g/mL and 16 PU 02 g/mL for 10 mg/kg and 30 mg/kg VRC01, respectively11,12. The concentration required for safety Mouse monoclonal to EphA4 from HIV illness is one of the secondary endpoints of the AMP tests. Based on non-human primate models, it is estimated that safety.